With the newly synthesized adiponectin receptor agonist, ADP355, and the defined adiponectin receptors in the lung, the role of adiponectin in the aforementioned inflammatory states, and its function as pattern recognition molecules, we expect that ADP355 would significantly benefit patients with obesity related lung injury. Here, ADIPOQ is linked to obesity disorder.